Australian Cannabis Producer Little Green Pharma Reports Record Revenue, 80% Increase In European Sales QoQ
Australian Cannabis Producer Little Green Pharma Reports Record Revenue, 80% Increase In European Sales QoQ
The company noted that the German, U.K. and French cannabis markets are driving strong growth in European industry demand. In the reporting quarter, the company had a 60% increase in flower sales to Europe, with more than a 110% increase in French oil sales.Australia-based cannabis grower and producer Little Green Pharma (ASX: LPG) reported its financial results for the quarter ended Sep 30, revealing unaudited record revenue of AU$10.2 million ($6.85 million). This marks a 40% increase from the prior quarter and nearly 60% from the corresponding quarter last year.
總部位於澳洲的大麻種植和生產商Little Green Pharma (ASX: LPG) 報告了截至9月30日的季度財務業績，披露了未經審計的創紀錄營業收入達到1020萬澳元（685萬美元）。這標誌着與上個季度相比增長了40％，與去年同期相比增長了近60％。
By product category, the company saw a 45% increase in oil sales, driven by growth in both France and Australia, and over a 35% increase in flower sales, driven by both the company's brands and white-label sales. At the same time, vaporizer sales declined 20%.
按產品類別劃分，該公司的油銷售增長了45％，主要得益於法國和澳大利亞市場的增長，花卉銷售增長了35％以上，主要得益於公司品牌和白標銷售的增長。與此同時，霧化器銷售下降了20％。
Quarterly Financial Highlights
季度財務亮點
- Cash receipts of AU$10.8 million, up more than 30% from the prior quarter;
- Net operating cash inflow of more than AU$1.0 million, resulting in a cash-flow-positive quarter of AU$600,000;
- Cost savings of AU$500,000 per year expected from subcontracting Australian cultivation operations;
- Cash in bank of AU$4.8 million up from AU$4.3 million.
- 現金收入達1080萬澳元，比上個季度增長了30％以上；
- 超過100萬澳元的淨經營現金流入，導致本季度的現金流爲600,000澳元；
- 預計從分包澳大利亞種植業務中節省每年50萬澳元；
- 銀行現金爲480萬澳元，高於430萬澳元。
Read Also: Cannabis Earnings Update: Marijuana Lenders And Top Operator To Report Results, Here's What Investors Need To Know
閱讀更多：大麻股收益更新：大麻借款人和頂級運營商將發佈業績報告，投資者需要了解的內容
- Get Benzinga's exclusive analysis and the top news about the cannabis industry and markets daily in your inbox for free. Subscribe to our newsletter here. If you're serious about the business, you can't afford to miss out.
- 獲取Benzinga獨家分析和關於大麻行業和市場的頭條新聞，每天免費發送到您的收件箱。在這裏訂閱我們的通訊。如果您對這項業務認真，就不能錯過。
European Potential
歐洲潛力
The company noted that the German, U.K. and French cannabis markets are driving strong growth in European industry demand. In the reporting quarter, the company had a 60% increase in flower sales to Europe, with more than a 110% increase in French oil sales.
該公司指出，德國、英國和法國的大麻市場正推動歐洲行業需求的強勁增長。在報告季度，該公司向歐洲花銷售增長了60％，法國油銷售增長超過110％。
The company recently revealed it expects France to fully legalize medical marijuana in 2025. According to the company's chief executive Paul Long, this could shift the majority of French people, who consume cannabis illegally, to medical use. According to the United Nations, some 6.8 million French people use marijuana illegally.
該公司最近透露，預計法國將在2025年全面合法化醫用大麻。根據該公司首席執行官保羅·朗的說法，這將使法國大多數非法使用大麻的人轉向醫療用途。根據聯合國的數據，約680萬名法國人非法使用大麻。
"People have this preconceived idea that cannabis is ... just chasing a high," Long previously said. "What we've seen [with] the patients coming from the illicit market to the medical [is] the lion's share — 70 to 80% — have actually been self-prescribed."
"人們普遍認爲大麻只是爲了追求高潮，" 朗此前表示。"我們觀察到，從非法市場轉向醫療的患者中，70％至80％實際上是自行開藥的。"
According to data from the Office of Drug Control, Australia produced 23 tons for the domestic market in 2022, with some 1,500 kg exported overseas. The industry contends that these figures will grow significantly as Europe updates its laws.
根據藥物管制局的數據，澳大利亞在2022年爲國內市場生產了23噸，在境外出口了1500公斤。該行業認爲，隨着歐洲法律的更新，這些數字將顯著增長。
- France's Cannabis Plans Face Delays, Israel's Secret Weed Lab And More Global Updates
- 法國的大麻計劃面臨延遲，以色列的祕密大麻實驗室及全球其他資訊更新
Photo: Courtesy of Branding Pot via Shutterstock
圖片：由Brand Pot通過Shutterstock提供。
譯文內容由第三人軟體翻譯。
